Review anchor
Tyrosine-protein kinase Lck
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Tyrosine-protein kinase Lck
CHEMBL258
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Lck as ChEMBL target CHEMBL258, mapped to UniProt P06239. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL258
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P06239
Tyrosine-protein kinase Lck
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Tyrosine-protein kinase Lck matters
Tyrosine-protein kinase Lck is reviewed as Tyrosine-protein kinase Lck (UniProt P06239); Tyrosine-protein kinase Lck shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 70 approved drugs, 6849 compounds, and 1338 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Tyrosine-protein kinase Lck
Tyrosine-protein kinase Lck Sequence length is 509 aa.
Review this target as Tyrosine-protein kinase Lck, mapped to UniProt P06239. Sequence length is 509 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P06239
Protein
Disease context
chromophobe renal cell carcinoma
Tyrosine-protein kinase Lck shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PAZOPANIB HYDROCHLORIDE.
Start review with chromophobe renal cell carcinoma because it currently carries approved-linked support. Linked drugs include PAZOPANIB HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 70 approved drugs, 6849 compounds, and 1338 assays for this target. The dominant activity type is IC50. CHEMBL215969 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL215969 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
70 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Tyrosine-protein kinase Lck matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P06239, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why chromophobe renal cell carcinoma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
6849
Total Compounds
1338
Total Assays
70
Approved Drugs
IC50: 4007.0, KI: 1888.0, EC50: 409.0, KD: 505.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL215969
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL458333
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL566813
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL566284
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL212181
|
10.2 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
TIRABRUTINIB
CHEMBL4071161
|
2020 |
|
|
PEXIDARTINIB
CHEMBL3813873
|
2019 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
ZANUBRUTINIB
CHEMBL3936761
|
2019 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
DACOMITINIB ANHYDROUS
CHEMBL2110732
|
2018 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
DABRAFENIB
CHEMBL2028663
|
2013 |
|
|
AFATINIB DIMALEATE
CHEMBL2105712
|
2013 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
TOFACITINIB CITRATE
CHEMBL2103743
|
2012 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
DASATINIB ANHYDROUS
CHEMBL1421
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
|
|
IMATINIB
CHEMBL941
|
2001 |
|
|
TANNIC ACID
CHEMBL506247
|
1982 |
|
|
ACETIC ACID
CHEMBL539
|
1982 |
Source Header